Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$0.64
C$0.64
C$0.38
C$8.17
C$90.27MN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.87
+7.1%
$8.74
$2.65
$13.70
$489.12M2.35618,180 shs755,986 shs
Geron Co. stock logo
GERN
Geron
$3.73
-0.3%
$3.30
$1.64
$4.30
$2.21B0.5510.87 million shs2.83 million shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$1.73
$1.38
$3.79
$117.93M1.08126,298 shs141,800 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.00%0.00%0.00%0.00%0.00%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-1.61%-5.16%-2.00%-17.88%+124.77%
Geron Co. stock logo
GERN
Geron
-1.58%+0.27%+2.75%+80.68%+20.65%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
3.1056 of 5 stars
4.52.00.00.01.82.50.6
Geron Co. stock logo
GERN
Geron
3.4985 of 5 stars
4.41.00.01.31.41.70.6
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
3.00
Buy$14.3382.13% Upside
Geron Co. stock logo
GERN
Geron
2.80
Moderate Buy$6.1063.54% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/A

Current Analyst Ratings

Latest FULC, GERN, LCI, CTST, and REPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2024
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00
5/14/2024
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00
5/13/2024
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$6.00 ➝ $15.00
5/2/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/30/2024
Geron Co. stock logo
GERN
Geron
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$4.50
4/29/2024
Geron Co. stock logo
GERN
Geron
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/11/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/10/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/15/2024
Geron Co. stock logo
GERN
Geron
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
(Data available from 5/14/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$35.22M2.56N/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$2.81M174.06N/AN/A$3.80 per share2.07
Geron Co. stock logo
GERN
Geron
$240K9,218.23N/AN/A$0.46 per share8.11
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$75.36M0.00N/AN/A$0.90 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CTST
CannTrust
-C$10.46MN/A0.00N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$97.33M-$1.58N/AN/AN/A-3,470.05%-36.65%-33.62%8/1/2024 (Estimated)
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.35N/AN/AN/A-38,730.00%-68.16%-47.26%8/1/2024 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/A

Latest FULC, GERN, LCI, CTST, and REPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/28/2024Q4 23
Geron Co. stock logo
GERN
Geron
-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million    
2/27/2024Q4 2023
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.44-$0.40+$0.04-$0.40$0.65 million$0.87 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
17.71
17.71
Geron Co. stock logo
GERN
Geron
0.03
3.67
3.67
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
2.27
3.24
2.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.03%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Geron Co. stock logo
GERN
Geron
73.71%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
62.34%

Insider Ownership

CompanyInsider Ownership
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
4.10%
Geron Co. stock logo
GERN
Geron
3.00%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
14.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CTST
CannTrust
576141.49 millionN/AOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7662.15 million59.61 millionOptionable
Geron Co. stock logo
GERN
Geron
141593.13 million575.34 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
18556.42 million48.41 millionOptionable

FULC, GERN, LCI, CTST, and REPH Headlines

Recent News About These Companies

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
Mankind Pharma share price
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
Aurobindo Pharma Ltd.
Sun Pharma reports "information security incident"; isolates impacted IT assets
Societal CDMO Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

CannTrust logo

CannTrust

NYSE:CTST
CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.
Fulcrum Therapeutics logo

Fulcrum Therapeutics

NASDAQ:FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Geron logo

Geron

NASDAQ:GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
Recro Pharma logo

Recro Pharma

NASDAQ:REPH
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.